WHAT IS CLAIMED IS:

1. Use of an ophthalmological composition in the manufacture of a medicament for the treatment of allergies, wherein said ophthalmological composition comprises from 0.005% to 0.050% w/v brimonidine and from 0.025% to 0.035% w/v ketotifen, wherein w/v denotes weight by total volume of the composition.

2. The use of claim 1, wherein the ophthalmological composition further comprises a nonionic surfactant, hydroxypropylmethyl cellulose, a buffer and optionally, sorbate.

3. Use of a composition as defined in claim 1 in the manufacture of a medicament for treating or preventing an allergic response in a subject in need thereof.

4. A composition for the treatment of allergic conjunctivitis comprising:

0.035% w/v ketotifen fumarate;

0.025% w/v brimonidine;

2.5% w/v polysorbate;

from 0.1% to 1.2% w/v hydroxypropylmethyl cellulose;

4 millimolar citrate buffer; and

optionally, 0.1% w/v sorbate,

wherein the composition has a pH of 6.5.

5. The use according to claim 1, wherein brimonidine is at a concentration from 0.01% to 0.025% w/v.

6. Use of an ophthalmological composition in the manufacture of a medicament for the treatment of allergies, wherein said ophthalmological composition comprises from 0.01% to 0.025% w/v brimonidine and from 0.025% to 0.035% w/v ketotifen, wherein w/v denotes weight by total volume of the composition.

7. The use according to claim 5, wherein the ophthalmological composition further comprises a nonionic surfactant, hydroxypropyl methyl cellulose, a buffer and optionally, sorbate.

8. The use according to claim 1, wherein brimonidine is at a concentration of about 0.025% w/v.

9. The use according to claim 1, wherein ketotifen comprises ketotifen fumarate.

10. The use according to claim 5, wherein the ophthalmological composition comprises an ophthalmic drop.

11. The use according to claim 8, wherein the ophthalmological composition comprises an ophthalmic drop.